[Form 4] Co-Diagnostics, Inc. Insider Trading Activity
Co-Diagnostics insider Richard David Abbott received 220,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. After the grant Abbott beneficially owns 350,438 shares of common stock, with the 220,000 RSUs vesting in six installments beginning 11/23/2025 and continuing every six months thereafter. The Form 4 was signed 08/15/2025 and lists Abbott as President and a director.
Il dirigente di Co-Diagnostics, Richard David Abbott, ha ricevuto 220.000 unit脿 di azioni vincolate (RSU) il 08/13/2025 nell'ambito del Piano di Incentivazione a Lungo Termine 2015 dell'emittente. Ciascuna RSU d脿 diritto, al verificarsi delle condizioni di maturazione, a ricevere una azione ordinaria. Dopo la concessione Abbott detiene beneficiariamente 350.438 azioni ordinarie; le 220.000 RSU matureranno in sei tranche a partire dal 11/23/2025 e poi ogni sei mesi. Il Modulo 4 猫 stato firmato il 08/15/2025 e indica Abbott come Presidente e amministratore.
El directivo de Co-Diagnostics, Richard David Abbott, recibi贸 220.000 unidades de acciones restringidas (RSU) el 08/13/2025 bajo el Plan de Incentivos a Largo Plazo 2015 del emisor. Cada RSU representa el derecho contingente a recibir una acci贸n ordinaria al consolidarse. Tras la concesi贸n, Abbott posee de forma beneficiaria 350.438 acciones ordinarias; las 220.000 RSU se consolidar谩n en seis pagos a partir del 11/23/2025 y cada seis meses despu茅s de esa fecha. El Formulario 4 fue firmado el 08/15/2025 y registra a Abbott como Presidente y director.
Co-Diagnostics鞚� 鞛勳洂 毽矘霌� 雿办澊牍勲摐 鞎犽炒韸�(Richard David Abbott)電� 氚滍枆須岇偓鞚� 2015雲� 鞛リ赴 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 2025/08/13鞐� 220,000欤检潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 靾橃棳氚涭晿鞀惦媹雼�. 臧� RSU電� 甓岆Μ臧� 靹彪霅橂┐ 氤错喌欤� 1欤茧ゼ 靾橂牴頃� 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃╇媹雼�. 靾橃棳 頉� 鞎犽炒韸鸽姅 齑� 350,438欤检潣 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 220,000欤检潣 RSU電� 2025/11/23攵�韯� 鞁滌瀾頃� 6須� 攵勴暊搿� 毵� 6臧滌洈毵堧嫟 氩犾姢韺呺惄雼堧嫟. 靹滌嫕 4(Form 4)電� 2025/08/15鞐� 靹滊獏霅橃棃瓿� 鞎犽炒韸鸽姅 靷灔 瓴� 鞚挫偓搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Le dirigeant de Co-Diagnostics, Richard David Abbott, a re莽u 220 000 unit茅s d'actions restreintes (RSU) le 13/08/2025 dans le cadre du Plan d'Incitation 脿 Long Terme 2015 de l'茅metteur. Chaque RSU repr茅sente le droit conditionnel de recevoir une action ordinaire lors de la lev茅e des conditions. Apr猫s l'attribution, Abbott d茅tient 脿 titre b茅n茅ficiaire 350 438 actions ordinaires ; les 220 000 RSU seront acquises en six versements 脿 partir du 23/11/2025 puis tous les six mois. Le Formulaire 4 a 茅t茅 sign茅 le 15/08/2025 et mentionne Abbott en tant que Pr茅sident et administrateur.
Der Insider von Co-Diagnostics, Richard David Abbott, erhielt am 13.08.2025 220.000 Restricted Stock Units (RSUs) im Rahmen des Long Term Incentive Plans 2015 des Emittenten. Jede RSU gew盲hrt das bedingte Recht, bei Vesting eine Stammaktie zu erhalten. Nach der Zuteilung h盲lt Abbott wirtschaftlich 350.438 Stammaktien; die 220.000 RSUs vesten in sechs Tranchen beginnend am 23.11.2025 und danach alle sechs Monate. Das Formular 4 wurde am 15.08.2025 unterschrieben und f眉hrt Abbott als President und Direktor auf.
- 220,000 RSUs granted under the Issuer's 2015 Long Term Incentive Plan, explicitly stated in the filing
- Each RSU converts to one share upon vesting, as described in the document
- Post-grant beneficial ownership disclosed: 350,438 shares are reported following the transaction
- None.
Insights
TL;DR: A routine executive equity grant increases the reporting person鈥檚 potential stake by 220,000 RSUs, vesting over three years.
The filing documents a standard equity compensation grant to the company President under the 2015 Long Term Incentive Plan. The RSUs convert one-for-one into common shares upon vesting and raise reported beneficial ownership to 350,438 shares. The staggered vesting schedule beginning 11/23/2025 implies retention incentives tied to future service rather than immediate dilution. No cash exercise price is reported.
TL;DR: Disclosure shows a clear, plan-based RSU grant to a named officer with defined vesting dates; disclosure appears complete and routine.
This Form 4 specifies the grant source, unit-to-share conversion, and a six-installment vesting timetable, meeting typical Section 16 disclosure requirements. The report identifies Abbott s roles and provides the post-grant beneficial ownership total. There are no amendments, derivative transactions, or peculiar transfer arrangements disclosed.
Il dirigente di Co-Diagnostics, Richard David Abbott, ha ricevuto 220.000 unit脿 di azioni vincolate (RSU) il 08/13/2025 nell'ambito del Piano di Incentivazione a Lungo Termine 2015 dell'emittente. Ciascuna RSU d脿 diritto, al verificarsi delle condizioni di maturazione, a ricevere una azione ordinaria. Dopo la concessione Abbott detiene beneficiariamente 350.438 azioni ordinarie; le 220.000 RSU matureranno in sei tranche a partire dal 11/23/2025 e poi ogni sei mesi. Il Modulo 4 猫 stato firmato il 08/15/2025 e indica Abbott come Presidente e amministratore.
El directivo de Co-Diagnostics, Richard David Abbott, recibi贸 220.000 unidades de acciones restringidas (RSU) el 08/13/2025 bajo el Plan de Incentivos a Largo Plazo 2015 del emisor. Cada RSU representa el derecho contingente a recibir una acci贸n ordinaria al consolidarse. Tras la concesi贸n, Abbott posee de forma beneficiaria 350.438 acciones ordinarias; las 220.000 RSU se consolidar谩n en seis pagos a partir del 11/23/2025 y cada seis meses despu茅s de esa fecha. El Formulario 4 fue firmado el 08/15/2025 y registra a Abbott como Presidente y director.
Co-Diagnostics鞚� 鞛勳洂 毽矘霌� 雿办澊牍勲摐 鞎犽炒韸�(Richard David Abbott)電� 氚滍枆須岇偓鞚� 2015雲� 鞛リ赴 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 2025/08/13鞐� 220,000欤检潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 靾橃棳氚涭晿鞀惦媹雼�. 臧� RSU電� 甓岆Μ臧� 靹彪霅橂┐ 氤错喌欤� 1欤茧ゼ 靾橂牴頃� 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃╇媹雼�. 靾橃棳 頉� 鞎犽炒韸鸽姅 齑� 350,438欤检潣 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 220,000欤检潣 RSU電� 2025/11/23攵�韯� 鞁滌瀾頃� 6須� 攵勴暊搿� 毵� 6臧滌洈毵堧嫟 氩犾姢韺呺惄雼堧嫟. 靹滌嫕 4(Form 4)電� 2025/08/15鞐� 靹滊獏霅橃棃瓿� 鞎犽炒韸鸽姅 靷灔 瓴� 鞚挫偓搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Le dirigeant de Co-Diagnostics, Richard David Abbott, a re莽u 220 000 unit茅s d'actions restreintes (RSU) le 13/08/2025 dans le cadre du Plan d'Incitation 脿 Long Terme 2015 de l'茅metteur. Chaque RSU repr茅sente le droit conditionnel de recevoir une action ordinaire lors de la lev茅e des conditions. Apr猫s l'attribution, Abbott d茅tient 脿 titre b茅n茅ficiaire 350 438 actions ordinaires ; les 220 000 RSU seront acquises en six versements 脿 partir du 23/11/2025 puis tous les six mois. Le Formulaire 4 a 茅t茅 sign茅 le 15/08/2025 et mentionne Abbott en tant que Pr茅sident et administrateur.
Der Insider von Co-Diagnostics, Richard David Abbott, erhielt am 13.08.2025 220.000 Restricted Stock Units (RSUs) im Rahmen des Long Term Incentive Plans 2015 des Emittenten. Jede RSU gew盲hrt das bedingte Recht, bei Vesting eine Stammaktie zu erhalten. Nach der Zuteilung h盲lt Abbott wirtschaftlich 350.438 Stammaktien; die 220.000 RSUs vesten in sechs Tranchen beginnend am 23.11.2025 und danach alle sechs Monate. Das Formular 4 wurde am 15.08.2025 unterschrieben und f眉hrt Abbott als President und Direktor auf.
FAQ
What did Co-Diagnostics (CODX) report on the Form 4 for Richard David Abbott?
How many shares does Abbott beneficially own after the reported transaction?
What is the vesting schedule for the RSUs granted to Abbott?
Under what plan were the RSUs granted?
Does the filing show a cash price for the RSUs or any exercise price?
